MaRS Impact AI – 2024

Published on January 25, 2024

On February 22 2024, MaRS Impact AI brings together the leading voices in AI with one common goal: responsibly commercializing AI innovation.

The post MaRS Impact AI – 2024 appeared first on MaRS Discovery District.

Continue reading on website
Other news

Amgen British Columbia Completes State of the Art Lab Expansion

January 25, 2024
BURNABY, BC – Amgen, one of the world’s leading biotechnology companies, announced the completion of a 4500 square foot expansion, capping off a $27 million investment in its state-of-the-art Canadian research laboratory in Burnaby. This development further increases the site’s capacity to discover and develop pioneering medical treatments and accelerate delivery of therapeutics to patients suffer

Bold Therapeutics Announces Positive Phase 2 Safety and Efficacy Results for BOLD-100 in Advanced Metastatic Colorectal Cancer at ASCO GI 2024

January 25, 2024
VANCOUVER, BC, -- Bold Therapeutics, a clinical-stage biopharmaceutical company developing novel metallotherapeutics, presented positive Phase 2 safety and efficacy data in advanced metastatic colorectal cancer (mCRC) patients treated with BOLD-100 in combination with FOLFOX previously treated with FOLFOX/CAPOX at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium